BRIEF-Revelation Biosciences, Inc., A Life Sciences Company Developing Therapeutics And Diagnostics For Respiratory Viral Infections, Including Covid-19, To Become Publicly Traded Through A Merger With Petra Acquisition, Inc.

Reuters

30 Aug 2021

Aug 30 (Reuters) - Petra Acquisition Inc :

* REVELATION BIOSCIENCES, INC., A LIFE SCIENCES COMPANY DEVELOPING THERAPEUTICS AND DIAGNOSTICS FOR RESPIRATORY VIRAL INFECTIONS, INCLUDING COVID-19, TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH PETRA ACQUISITION, INC.

* PETRA ACQUISITION INC - COMBINED COMPANY EXPECTED TO HAVE A POST-TRANSACTION PRO FORMA TOTAL ENTERPRISE VALUE OF APPROXIMATELY $128 MILLION

* PETRA ACQUISITION INC - COMBINED COMPANY WILL BE LISTED ON NASDAQ UNDER TICKER SYMBOL "REVB"

* PETRA ACQUISITION INC - PETRA, WHICH CURRENTLY HOLDS APPROXIMATELY $73 MILLION OF CASH IN TRUST, WILL BE RENAMED TO REVELATION BIOSCIENCES, INC

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2163000196"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2163000196\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2163000196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-30 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2163000196","market":"us","top_or_hot":-1,"title":"BRIEF-Revelation Biosciences, Inc., A Life Sciences Company Developing Therapeutics And Diagnostics For Respiratory Viral Infections, Including Covid-19, To Become Publicly Traded Through A Merger With Petra Acquisition, Inc.","media":"Reuters","content":"<html><body><p>Aug 30 (Reuters) - <a href=\"https://laohu8.com/S/PAICW\">Petra Acquisition Inc</a>   :</p><p>   * REVELATION BIOSCIENCES, INC., A LIFE SCIENCES COMPANY DEVELOPING THERAPEUTICS AND DIAGNOSTICS FOR RESPIRATORY VIRAL INFECTIONS, INCLUDING COVID-19, TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH PETRA ACQUISITION, INC.</p><p>   * PETRA ACQUISITION INC - COMBINED COMPANY EXPECTED TO HAVE A POST-TRANSACTION PRO FORMA TOTAL ENTERPRISE VALUE OF APPROXIMATELY $128 MILLION</p><p>   * PETRA ACQUISITION INC - COMBINED COMPANY WILL BE LISTED ON NASDAQ UNDER TICKER SYMBOL \"REVB\"</p><p>   * PETRA ACQUISITION INC - PETRA, WHICH CURRENTLY HOLDS APPROXIMATELY $73 MILLION OF CASH IN TRUST, WILL BE RENAMED TO REVELATION BIOSCIENCES, INC</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Revelation Biosciences, Inc., A Life Sciences Company Developing Therapeutics And Diagnostics For Respiratory Viral Infections, Including Covid-19, To Become Publicly Traded Through A Merger With Petra Acquisition, Inc.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Revelation Biosciences, Inc., A Life Sciences Company Developing Therapeutics And Diagnostics For Respiratory Viral Infections, Including Covid-19, To Become Publicly Traded Through A Merger With Petra Acquisition, Inc.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-30 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aug 30 (Reuters) - <a href=\"https://laohu8.com/S/PAICW\">Petra Acquisition Inc</a>   :</p><p>   * REVELATION BIOSCIENCES, INC., A LIFE SCIENCES COMPANY DEVELOPING THERAPEUTICS AND DIAGNOSTICS FOR RESPIRATORY VIRAL INFECTIONS, INCLUDING COVID-19, TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH PETRA ACQUISITION, INC.</p><p>   * PETRA ACQUISITION INC - COMBINED COMPANY EXPECTED TO HAVE A POST-TRANSACTION PRO FORMA TOTAL ENTERPRISE VALUE OF APPROXIMATELY $128 MILLION</p><p>   * PETRA ACQUISITION INC - COMBINED COMPANY WILL BE LISTED ON NASDAQ UNDER TICKER SYMBOL \"REVB\"</p><p>   * PETRA ACQUISITION INC - PETRA, WHICH CURRENTLY HOLDS APPROXIMATELY $73 MILLION OF CASH IN TRUST, WILL BE RENAMED TO REVELATION BIOSCIENCES, INC</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRCT","symbol_name":"Cricut, Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2163000196","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2163000196","pubTimestamp":1630317669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Aug 30 (Reuters) - Petra Acquisition Inc   :   * REVELATION BIOSCIENCES, INC., A LIFE SCIENCES COMPA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRCT":"Cricut, Inc.","TERN":"Terns Pharmaceuticals, Inc."},"translate_title":"简讯-启示录生物科学公司是一家生命科学公司，为包括新冠肺炎在内的呼吸道病毒感染开发治疗和诊断，将通过与佩特拉收购公司的合并上市。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRCT":1,"PAIC":0.9,"PAICU":1,"TERN":1},"content_text":"Aug 30 (Reuters) - Petra Acquisition Inc   :   * REVELATION BIOSCIENCES, INC., A LIFE SCIENCES COMPANY DEVELOPING THERAPEUTICS AND DIAGNOSTICS FOR RESPIRATORY VIRAL INFECTIONS, INCLUDING COVID-19, TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH PETRA ACQUISITION, INC.   * PETRA ACQUISITION INC - COMBINED COMPANY EXPECTED TO HAVE A POST-TRANSACTION PRO FORMA TOTAL ENTERPRISE VALUE OF APPROXIMATELY $128 MILLION   * PETRA ACQUISITION INC - COMBINED COMPANY WILL BE LISTED ON NASDAQ UNDER TICKER SYMBOL \"REVB\"   * PETRA ACQUISITION INC - PETRA, WHICH CURRENTLY HOLDS APPROXIMATELY $73 MILLION OF CASH IN TRUST, WILL BE RENAMED TO REVELATION BIOSCIENCES, INCSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}